文献速递免疫规划职业卫生

两剂BBIBP-CorV疫苗在高风险职业人群中诱导免疫持久性的预测因素

Predictors of immune persistence induced by two-dose BBIBP-CorV vaccine in high-risk occupational population.
PubMed 文献 · Vaccine · 2023-08-19

研究纳入809名受试者随机分配至0-14天、0-21天或0-28天两剂接种程序,对第二剂后28天中和抗体滴度≥16者随访至第10个月。多变量Cox回归和列线图模型显示,年龄≥50岁与应答丢失高风险相关,0-28天程序、流感疫苗接种史和女性倾向于维持免疫持久性。列线图具有中等区分度和良好校准。

要点

  • 年龄≥50岁与中和抗体应答丢失高风险相关(aHR=3.556)。
  • 0-28天程序、流感疫苗接种史和女性倾向于维持免疫持久性。
  • 列线图预测模型C-index为0.711,AUC为0.731,校准良好。

核心结论

  • 从第二剂BBIBP-CorV疫苗接种后28天至10个月,中和抗体水平大幅下降,尤其在男性、50岁及以上人群、0-14天程序组和无流感疫苗接种史者中。

研究设计与样本

  • 初始研究共招募809名受试者,按1:1:1随机分配至0-14天、0-21天或0-28天两剂接种程序组。
  • 第二剂后28天中和抗体滴度≥16的受试者在第3、6和10个月接受随访。
  • 采用多变量Cox比例风险回归模型和列线图模型识别与第二剂后10个月内维持中和抗体水平相关的预测因素。

主要发现

  • 共744名受试者在第二剂后28天接受随访。
  • 年龄≥50岁与应答丢失(滴度<16)高风险相关(aHR=3.556,95%CI:1.141-4.884,P=0.028)。
  • 0-28天组(aHR=0.403,95%CI:0.177-0.919,P=0.031)、有流感疫苗接种史(aHR=0.468,95%CI:0.267-0.921,P=0.033)或女性(aHR=0.542,95%CI:0.269-0.935,P=0.035)倾向于在第二剂后10个月内维持免疫持久性。
  • 列线图具有中等区分度(C-index:0.711,95%CI:0.652-0.770;AUC:0.731,95%CI:0.663-0.792)和良好校准。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The immune protection from infection may wane over time as neutralizing antibody levels decline. We aimed to develop a nomogram to predict long-term immune persistence induced by two-dose BBIBP-CorV vaccine and calculate the neutralizing antibody decline probability of individuals. METHODS: In the initial study, a total of 809 participants were recruited and randomly allocated (1:1:1) to vaccination group with three two-dose schedules on days 0 and 14, 0 and 21, or 0 and 28. The participants with neutralizing antibody titers of 16 or above on day 28 after the second dose were followed up at month 3, 6 and 10. Multivariable Cox proportional hazards regression model and nomogram model were used to identify predictors associated with maintaining of neutralizing antibody levels during 10 months after the second dose. RESULTS: A total of 744 participants followed up at day 28 after the second dose. The participants with age ≥ 50 (aHR = 3.556, 95 %CI: 1.141-4.884, P = 0.028) were associated with a high risk of response loss (titers < 16). The participants who were in 0-28 d group (aHR = 0.403, 95 %CI: 0.177-0.919, P = 0.031), had an influenza vaccination history (aHR = 0.468, 95 %CI: 0.267-0.921, P = 0.033) or were female (aHR = 0.542, 95 %CI: 0.269-0.935, P = 0.035) tended to maintain immune persistence during 10 months after the second dose. The nomogram was constructed and showed moderate discrimination[C-index:0.711 (95 %CI: 0.652-0.770); AUC: 0.731 (95 %CI: 0.663-0.792)] and good calibration. CONCLUSIONS: From 28 days to 10 months after receipt of the second dose of the BBIBP-CorV vaccine, neutralizing antibody levels were substantially decreased, especially among men, among persons 50 years of age or older, among persons with the 0-14 d group, and among persons without history of influenza vaccination. TRIAL REGISTRATION: Chinese Clinical Trial Registry, ChiCTR2100041705, ChiCTR2100041706.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Yao T, Guo Y, Xu X, et al. Predictors of immune persistence induced by two-dose BBIBP-CorV vaccine in high-risk occupational population. Vaccine. 2023. PMID: 37604725. doi:10.1016/j.vaccine.2023.08.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。